drugset / Trial / NCT01366326

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

NCT01366326

Phase 1 Completed 20 enrolled Bausch Health Americas, Inc.
NaSingle-groupOpen-labelTreatment

Summary

MNTX 1109 is a single center, open label study, composed of normal healthy adult subjects to evaluate the PK of MNTX and its metabolites administered once daily as a subcutaneous (SC) injection for a period of seven days. Blood samples will be obtained at screening and for drug concentration data.

Timeline

Start
2010-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified Subcutaneous

Indications

No indication recorded.